In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been demonstrated, but the frequency and the functional consequence of IL-22 signaling have not been addressed. This study aims at analyzing the cellular effects of IL-22 on lung carcinoma cell lines and the prognostic impact of IL-22 tissue expression in lung cancer patients. Methods: Biological effects of IL-22 signaling were investigated in seven lung cancer cell lines by Western blot, flow cytometry, realtime polymerase chain reaction, and proliferation assays. Tumor tissue specimens of two cohorts with a total of 2300 lung cancer patients were tested for IL-22 expression by immunohistochemistry. IL-22 serum concentrations were analyzed in 103 additional patients by enzyme-linked immunosorbent assay. Results: We found the IL-22 receptor 1 (IL-22-R1) to be expressed in six of seven lung cancer cell lines. However IL-22 signaling was functional in only four cell lines, where IL-22 induced signal transducer activator of transcription 3 phosphorylation and increased cell proliferation. Furthermore, IL-22 induced the expression of antiapoptotic B-cell lymphoma 2, but did not rescue tumor cells from carboplatin-induced apoptosis. Cisplatin-resistant cell lines showed a significant up-regulation of IL-22-R1 along with a stronger proliferative response to IL-22 stimulation. IL-22 was preferentially expressed in small-and large-cell lung carcinoma (58% and 46% of cases, respectively). However, no correlation between IL-22 expression by immunohistochemistry and prognosis was observed. Conclusion: IL-22 is frequently expressed in lung cancer tissue. Enhanced IL-22-R1 expression and signaling in chemotherapyrefractory cell lines are indicative of a protumorigenic function of IL-22 and may contribute to a more aggressive phenotype.
I
nterleukin-22 (IL-22) is a unique cytokine of the IL-10 family acting exclusively on interleukin-22-receptor 1 (IL-22-R1) positive epithelial cells.
1 IL-22 induces antimicrobial proteins such as defensins in epithelial cells, protects against damage, and promotes regeneration in injured tissues. 2 These functions, including up-regulation of antiapoptotic pathways and increased proliferation, are protective in acute inflammatory conditions and in tissue injury, 3, 4 but may be deleterious in chronic states where proliferation or antiapoptosis promote disease, as demonstrated in psoriasis. 5 Several signal transducers downstream of the IL-22-R1 have been described, including signal transducer activator of transcription (STAT)1 STAT5, extracellular-signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and p38. 6 In cancer cells, however, the main signaling pathway downstream of the IL-22-R1 is STAT3, which mediates most IL-22-induced effects. 2, 7, 8 In the lung, IL-22 has been found to be expressed by alveolar epithelial cells, macrophages, and T cells. 9, 10 Both exogenous IL-22 and IL-22 produced by immune cells protect lung tissue from acute injury induced by ventilation trauma or viral infection. 3, 11 Thus, the lung is an organ in which epithelial cells can react to IL-22 and resident cell populations are capable of producing IL-22. Interestingly, many cancer cell lines, including those of lung origin, express the IL-22-R1. studied IL-22 serum levels in lung cancer patients. Further, we investigated IL-22-R1 expression, signal transduction, and proliferative response to IL-22 in lung cancer cell lines.
PATIENTS AND METHODS

Patients and Patient-Derived Samples
Two tissue microarrays (TMAs) were established from a total of 203 (TMA1) and 2097 (TMA2) lung cancer specimens of archived tissue samples at the Institute of Pathology at the University Medical Center Hamburg-Eppendorf, the University Hospital Freiburg, and the Kantonspital Basel (collected between 1994 and 2006), respectively. All tissues were obtained from patients who were undergoing lobectomy or pneumectomy. Tissue samples were formalin-fixed (buffered neutral aqueous 4% solution), paraffin-embedded, and used for TMA construction, as previously described. 13 Hematoxylineosin-stained sections were used to define representative tumor regions. Tissue cylinders (0.6 mm in diameter) were then punched from that region of the block with the use of a self-developed semiautomated tissue arrayer.
14 Survival data were available for 1724 patients. The mean follow-up period was 29.1 months (range, 3-200 months). Survival data were either obtained from the cancer registry, or collected from the patients' attending physicians. All tissues included in these TMAs had been reviewed by an expert pathologist determining histological type and histological grade. The pathologically determined tumor stage (pT), nodal (pN), and metastasis (pM) status were obtained from the primary reports of the department of pathology. The collection and TMA-based screenings of human tumor samples were in compliance with the ethical principles for medical research established by the World Medical Association's Declaration of Helsinki in its current version. An overview of the patient cohort is given in Table 1 .
Serum samples from 103 patients with early-stage lung cancer were obtained from the Asklepios Biobank of Lung Diseases. All patients gave their informed consent.
Serum samples from age-and sex-matched healthy donors (n = 70) were provided by the Bavarian Red Cross (Blutspendedienst des Bayerischen Roten Kreuzes gemeinnützige GmbH).
Cell Lines
Lung cancer cell lines H187, H1339, LOU-NH91, HCC827, and A549 were purchased from the German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und Zellkultur (DSMZ), Braunschweig, Germany). The cisplatin-resistant cell lines H1339-R and HCC827-R have been described. 15 De novo cisplatin-resistant cell lines HCC827-R2 and A549-R were generated, as previously described.
15
Scratch Assay
Scratch assay was performed, as described. 16 Cells were stimulated for 4 hours in 1% fetal calf serum (FCS) medium (Dulbecco's Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute (RPMI) supplemented with 1% penicillin-streptomycin [PS] of 10,000 U/ml and 10,000 µg/ml stock solution; respectively) and 1% L-glutamine (of 200 mm stock solution) with or without IL-22 (Peprotech, Hamburg, Germany) or gardiquimod (InvivoGen, Toulouse, France) at the indicated concentrations. Cell-free area was measured and calculated using Image J software (freeware established by R. Stallmann and available for download under http://rsbweb.nih. gov/ij/download.html). Mitomycin C was used at 10 µg/ml.
Western Blot
Western blot was performed, as previously described. 17 Antibodies used included polyclonal antibody against IL-22-R1 (Sigma, St. Louis, MO), monoclonal antibody against pSTAT3 (Tyr705, clone B-7; Santa Cruz, Heidelberg, Germany), monoclonal antibody against STAT3 (clone F-2; Santa Cruz), polyclonal antibody against BCL-2 (N19, sc492; Santa 
Real-Time Polymerase Chain Reaction
Quantitative RT-PCR was performed as previously described. 17 The following primers were designed using the online Roche assay design center: IL-22-R1-fwd: 5′-TTA TTT TTC CAT TGT CTC TGT CCA -3′, IL-22-R1-rev: 5′-TGG CAG CAC ATT TCC TTG TAA CT -3′, HPRT-fwd: 5′ -CGA GCA AGA CGT TCA GTC CT -3′, and HPRT-rev: 5′ -TGA CCT TGA TTT ATT TTG CAT ACC-3′, together with the probes 28 and 73 of the Roche Universal Probe Library (Roche, Mannheim, Germany). Primer efficiency was determined experimentally by serial dilutions of cDNA at 2.13 for the IL-22-R1 primer pair and at 1.95 for the HPRT pair. Expression of IL-22-R1 relative to HPRT was calculated using the light cycler relative quantification software based on the formula: relative expression = NT × ETCpT/NR × ERCpR where NT is the number of target molecules at detection threshold Cp, NR is the number of reference molecules at detection threshold Cp, ET is the efficiency of target amplification, and ER is the efficiency of reference amplification.
Vitality and Proliferation Assay
For assessing cell vitality, cell titer blue assay was performed in accordance with the protocol of the manufacturer (Promega, Mannheim, Germany). Stimulation by or neutralization of IL-22 was performed in serum-free medium (DMEM or RPMI, 1% PS and 1% L-Glutamine). Positive controls for vitality or proliferation were assessed in culture medium supplemented as above including, in addition, 10% FCS. 
Apoptosis Assay by Annexin V-Propidium Iodide Staining
Cells were treated either with carboplatin (Ratiopharm, Ulm, Germany) at the indicated concentrations: STATTIC (10 µM) or IL-22 (100 ng/ml) for 48 hours in supplemented culture medium (DMEM or RPMI with 10% FCS, 1% PS and 1% L-Glutamine). Afterward, cells were stained with propidium iodide nucleic acid stain (Invitrogen, Paisley, United Kingdom) and annexin V allophycocyanin (APC)-conjugated antibody (ImmunoTools, Friesoythe, Germany). Cells were studied by flow cytometry using a FACS Canto II (Becton Dickinson, Heidelberg, Germany), and data were analyzed with Flow Jo software (Version 7.6.5; Tree Star Inc., Ashland, Oregon).
IL-22 Immunohistochemistry
Freshly cut 3-μm thick TMA sections were analyzed on 1 day in a single experiment. IL-22 expression was detected with a polyclonal rabbit antibody (ab18944; abcam) in a dilution of 1:150 after peroxidase blocking with H 2 O 2 (DAKO S2023; DAKO, Hamburg, Germany) for 10 minutes. Slides were pretreated at high-temperature in an autoclave (121°C) with citrate buffer, pH 6 for 5 minutes. The Envision system (DAKO 5007) was used to visualize immunostaining. The IL-22 antibody was pretested on a separate TMA containing biopsies of normal tissue (colon; n = 3; endometrium, n = 4, lung, n = 4, epididymidis, n = 2) as negative controls (no IL-22 expression) and biopsies with malignant tissue (colon cancer; n = 10), where IL-22 expression has been previously described (positive control) 18 . For each tissue spot, IL-22 staining was scored by cytosplasmatic staining intensity (0, 1+, 2+, or 3+) and by estimation of the fraction of positive tumor cells. A composite score was built from these two parameters according to the following scheme: Low expression was defined as a staining intensity of 0 and 1+ in less than 70% of tumor cells or a staining intensity of 2+ in less than 30% of tumor cells. Positive expression was defined as a staining intensity of 1+ in more than 70% of tumor cells, a staining intensity of 2+ in more than 30% of tumor cells, or a staining intensity of 3+.
Statistical Analyses
For statistics JMP 7.0 software (SAS institute Inc., Cary, NC) or GraphPad Prism Software, version 5.0b (GraphPad Software, LaJolla, CA) were used. All Student's t tests were two-sided and p values less than 0.05 were considered significant. Differences between experimental conditions were analyzed using the unpaired Student's t test. Regression analysis was used to compare variances. To study the relationship between IL-22 expression and clinical-pathological parameters, contingency table analysis and χ 2 test (likelihood) was used. Overall survival was analyzed by the Kaplan-Meier method and was compared using log-rank test.
RESULTS
Lung Cancer Cell Lines Express IL-22-R1 but React Heterogeneously to IL-22 Stimulation
Seven lung cancer cell lines were studied for the biological effects of IL-22 signaling: A549, HCC827, H1339, H187, LOU-NH91, HCC827-R, and H1339-R (the latter 2 cisplatinresistant). Six of seven cell lines (85%) were found positive for IL-22-R1 expression by Western blot and RT-PCR ( Fig. 1A and data not shown). None of the cell lines were found to express IL-22 (data not shown). To test for IL-22-R1 functionality, cell lines were stimulated with recombinant IL-22, and subsequent STAT3 phosphorylation was analyzed by Western blot ( and H187). The cell lines H1339, LOU-NH91, and HCC827 did not respond by STAT3 phosphorylation (see Fig. 1B for HCC827, data not shown for H1339 and LOU-NH91).
Specificity of the signaling was demonstrated using IL-22 neutralizing and IL-22-R1 blocking antibodies and a specific STAT3 phosphorylation inhibitor (Fig. 1D ).
IL-22 Induces Proliferation in IL-22 Responsive Lung Cancer Cell Lines
Lung cancer cell lines that are reactive to IL-22 as evidenced by STAT3 phosphorylation were tested for IL-22-induced proliferation. IL-22 stimulation resulted in an increase in proliferation as compared with unstimulated cells (Fig. 2A) . The observed effect was dependent on IL-22 signaling through STAT3 because IL-22-blocking antibodies and STAT3 inhibition completely suppressed IL-22-induced cell proliferation (Fig. 2B) . Subsequently, we investigated the impact of IL-22 on re-epithelialization in a standardized scratch assay. IL-22 induced faster re-epithelialization of the scratch as compared with the unstimulated control (Fig. 2C ). Because IL-22 stimulation showed no dose dependency between 100 and 50 ng/ml in proliferation assays, we chose to test the effect of IL-22 in scratch assay using 100 ng/ml and 10 ng/ml (Fig. 2C) . A trend toward a dose dependency was observed. Again, the faster reepithelialization was only observed in IL-22-sensitive cell lines (Fig. 2D) . Suppression of IL-22-mediated re-epithelialization by mitomycin C treatment, which blocks proliferation but not migration, indicates that replenishment of the scratch area is mediated predominantly by tumor cell proliferation (Fig. 2D) .
IL-22 Does Not Protect Lung Cancer Cell Lines from Chemotherapy-Induced Apoptosis
IL-22 has been described to protect epithelial cells from apoptosis through up-regulation of antiapoptotic proteins such as BCL-2. 19 We used the chemotherapeutic drug carboplatin, which induces apoptosis in cancer cells by cross-linking of DNA strands. Treatment with IL-22 had no impact on cell viability or on the rate of apoptosis in carboplatin-exposed A549 or HCC827-R cells (Fig. 3A, B 
Chemotherapy-Resistant Cell Lines Upregulate IL-22-R1 Expression and Signaling
Because resistance to standard chemotherapeutic agents such as cisplatin is a common event in lung cancer treatment, we attempted to determine whether drug-resistant cells have an altered response to IL-22. Cell lines A549 and HCC827 were repeatedly exposed to cisplatin, which resulted in resistance to both cisplatin and cisplatin-induced apoptosis (Fig. 4A and Supplementary Figure 1B , Supplemental Digital Content 1, http://links.lww.com/JTO/A434). These cell lines were designated A549-R and HCC827-R2, respectively. Interestingly, A549-R and HCC827-R2 up-regulated IL-22-R1 expression as assessed by RT-PCR and Western blot (Fig. 4B) . Up-regulation of IL-22-R1 expression correlated with a stronger IL-22-induced proliferative response as compared with passage-matched nonresistant controls (Fig. 4C ). These data indicate that cisplatinresistant cell lines are more sensitive to IL-22 signaling and this may contribute to the aggressive phenotype of these cells.
IL-22 Is Preferentially Expressed in Primary Large-and Small-Cell Lung Cancer
To further investigate how the above-described in vitro effects impact on human lung cancer disease, we first tested whether IL-22 is expressed in primary lung cancer tissue, by staining 203 samples from patients with NSCLC and smallcell lung cancer (SCLC) (TMA1; Table 2 ) for IL-22 expression. IL-22 was expressed in all histological subtypes with the highest positive proportion in SCLC (85%; Fig. 5A, B) . Adenocarcinoma (ADCA), bronchoalveolar carcinoma, and large-cell carcinoma exhibited similar expression rates with 54%, 45%, and 44%, respectively. Morphologically, the tumor tissue, that is, the cancer cells themselves mainly stained positive for IL-22 expression. Squamous cell carcinoma (SQCC) showed the least frequent expression of IL-22 (23%). To confirm these findings, we next analyzed a second cohort containing 2097 samples from patients with NSCLC (n = 2034; 97%) or SCLC (n = 63; 3%) for IL-22 expression (Table 3) . Of 2097 TMA tissue spots stained for IL-22 expression, 1815 spots (86%) were evaluable for IL-22 expression analysis. The remaining 282 samples were noninformative because of absence of tissue on the TMA or a lack of unequivocal tumor cells in the arrayed samples. Expression of IL-22 was again found in a majority of SCLC samples (58%; Fig. 1C ). Largecell carcinoma had the second highest proportion of IL-22 expression (46%; Fig. 1C) , whereas, ADCA, bronchoalveolar carcinoma, and SQCC expressed IL-22 only in smaller proportions of samples (33%, 24%, and 28%, respectively). Contingency table analysis confirmed a higher expression in SCLC and large-cell carcinoma compared with the other histological subtypes (p < 0.0001; Table 3 ). Expression of IL-22 by large-cell carcinoma is supported by the analysis of serum IL-22 levels in a small cohort (n = 103) of patients undergoing surgery for ADCA, SQCC, or large-cell carcinoma. Two of the three patients in this cohort with large-cell lung carcinoma had higher IL-22 concentrations in their serum (998 and 964 pg/ml) compared with matched healthy controls (mean 53 pg/ml), with ADCA (mean 28 pg/ml), or with SQCC (mean 
IL-22 Expression Does Not Correlate with Prognosis in Resected NSCLC and SCLC
We first tested the patient cohort of TMA2 for known prognostic parameters such as pathologically determined pT, pN, and pM. Advanced T stage (pT3 or pT4), positive nodal status (pN1-3), and pM1 all correlated significantly with reduced overall survival (p < 0.0001 for all comparisons, Supplementary Figure 2A , Supplemental Digital Content 2, http://links.lww.com/JTO/A435). Having established that the studied cohort is representative for standard prognostic factors, we analyzed the influence of IL-22 expression on prognosis in the complete cohort (Fig.  5D ) and in the different histological subtypes separately (Supplementary Figure 2B , Supplemental Digital Content 2, http://links.lww.com/JTO/A435). IL-22 did not correlate with prognosis in any of the groups analyzed ( Fig. 5D ; Supplementary Figure 2B , Supplemental Digital Content 2, http://links.lww.com/JTO/A435). Moreover, we found no significant difference in IL-22 expression between different tumor stages (Table 3) .
DISCUSSION
So far, a single study has reported IL-22 to be expressed in a small cohort of lung carcinoma samples. 7 The significance of this finding for the patients remained unclear. Our current study is the first to address the frequency of expression and the prognostic value of IL-22 expression in lung cancer. Analyzing two independent patient cohorts, we found SCLC and largecell carcinoma to predominantly express IL-22 among all subtypes analyzed. In IL-22-responsive cell lines (4 of 7), IL-22 induced STAT3-mediated proliferation but not migration or protection from chemotherapy-induced apoptosis. We found 3,9 Importantly, expression of IL-22-R1 has been found to be up-regulated in lung cancer samples. 21 However, because all lung cancer cell lines were found negative for IL-22 protein expression, expression of IL-22 in primary tissue may arise from nontumor cells or from the interaction between tumor and nontumor cells and stroma. The frequent expression we have found in large-cell lung correlates with the elevated serum concentrations we have found in large-cell lung cancer patients. No elevated serum concentrations were found in patients with the IL-22 low-expressing ADCA or SQCC. In contrast to the findings of Zhang et al., 7 who suggested a chemotherapy-protective role of IL-22 through Bcl-2 up-regulation, IL-22 had no impact on chemotherapy-induced apoptosis in the current study, irrespective of the mechanism of apoptosis induction (adduct formation with DNA for carboplatin or blockade of thymidine synthesis by 5-fluorouracil), despite a slight Bcl-2 up-regulation. This discrepancy may be explained by the only modest impact on apoptosis described in the previous study.
The impact of cisplatin resistance on the expression of the IL-22-R1 may reflect a response to cell stress induced by chemotherapy. Although the exact mechanism and the regulation of this receptor remains unaddressed, up-regulation of IL-22-R1 has been reported to be induced by proinflammatory cytokines such as interferon-α and tumor necrosis factor-α. 22, 23 The up-regulation of IL-22-R1 in a setting of acute stress may contribute to a rescue of these cells, if IL-22 is present. 23 Not surprisingly, none of the analyzed tumor cell lines secreted notable levels of IL-22, congruent with previous reports. 7 This discrepancy versus the positive IL-22 expression in primary tumor tissue may be because of differences in expression between cell lines and primary tumors observed in other contexts. 24 However, because IL-22 expression has not been demonstrated in healthy epithelial cells, the source of IL-22 in the tumor environment may be the infiltrating immune cells. In fact, tumor infiltrating IL-22-positive T cells have been demonstrated in lung cancer, hepatocellular carcinoma, and gastric cancer. [25] [26] [27] Other potentially IL-22 producing cells (e.g., Th17-cells) have been detected in several cancer types, including lung cancer. 28 In addition, IL-22 can be produced by NK and myeloid cells, also found in the tumor microenvironment. 29, 30 It is surprising that despite IL-22 expression in a substantial number of the tumors, we were unable to find a correlation with prognosis, as has been suggested for IL-22 in gastric and hepatocellular carcinoma. 26, 27 According to our data, there may be several explanations for this discrepancy: First, we have found lung cancer cell lines to respond heterogeneously to IL-22, which, if representative of the patients' situation, may indicate that not every cancer will respond to IL-22. Second, the impact of IL-22 on proliferation only and not on apoptosis may be insufficient to overcome the therapeutic effect of the operation performed in these patients. Third, IL-22-R1 expression may vary among tumor cells and because the receptor is a prerequisite for IL-22 reaction, IL-22 expression would need to be compared with IL-22-R1 expression, which according to our data directly impacts on IL-22 response. However, no loss or down-regulation of IL-22-R1 in cancer patients has been demonstrated so far. Most reports analyzing IL-22-R1 in lung cancer or other tumor types agree that IL-22-R1 is strongly expressed within all cancer tissues analyzed. 7, 21, 27 Accordingly, a receptor-based lack of effect of IL-22 may only be because of mutations in the coreceptor IL-10R2 or to downstream signaling defects, such as activating STAT3 mutations. 31, 32 Because most patients will receive chemotherapy at some point during the course of their disease, it seems possible, based on our observation, that chemotherapy-resistant cells are more prone to IL-22 stimulation. In this case tumor tissue IL-22 expression prognostic at a later time point in the disease course not covered by the tissue samples studied here. In conclusion, we found no evidence for IL-22 as a prognostic biomarker in early, potentially curable lung cancer. Further studies are needed to address the impact of IL-22 in advanced lung cancer, especially in SCLC and largecell lung cancer.
